Source: The European Journal of Health Economics. Unidade: EE
Subjects: CUSTOS DOS CUIDADOS DE SAÚDE, ECONOMIA DA SAÚDE, NEOPLASIAS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATUOKA, Jessica Yumi e KAHN, James G e SECOLI, Silvia Regina. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics, v. 20, n. Ju 2019, p. 487-499, 2019Tradução . . Disponível em: https://doi.org/10.1007/s10198-018-1011-1. Acesso em: 02 nov. 2024.APA
Matuoka, J. Y., Kahn, J. G., & Secoli, S. R. (2019). Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics, 20( Ju 2019), 487-499. doi:10.1007/s10198-018-1011-1NLM
Matuoka JY, Kahn JG, Secoli SR. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review [Internet]. The European Journal of Health Economics. 2019 ; 20( Ju 2019): 487-499.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1007/s10198-018-1011-1Vancouver
Matuoka JY, Kahn JG, Secoli SR. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review [Internet]. The European Journal of Health Economics. 2019 ; 20( Ju 2019): 487-499.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1007/s10198-018-1011-1